VANCOUVER, British Columbia, October 4, 2018 /PRNewswire/ --
Integrated Cannabis Company, Inc. (CSE: ICAN) (OTCQB:ICNAF) ("Integrated Cannabis "), is pleased to announce the successful completion and positive results of a controlled trial of its proprietary Sleep product.
The controlled 60 patient trial was completed with a renowned pain clinic in
"The unique formulation of ingredients in the X-SPRAYS™ sleep supplement contributed to a significant improvement in sleep quality together with a reduction in daytime sleepiness, pain, and depression, when compared to the control group. The study was conducted in a controlled and regulated clinical environment, which prohibits the test of cannabis products. Therefore the study was on our non-cannabinoid product. However, our experience with the infusion of CBD into the tested formulation has rendered profound increased benefits. Furthermore, we are actively seeking clinical study relationships in legal jurisdictions outside of North America for our cannabinoid-based products and expect to replicate the aforementioned study in the near term. The spray has the added benefit of being easy to use, is fast acting, promotes a superb night's rest and does not leave you feeling groggy in the morning," said Dr. Clive Spray, CSO of Integrated Cannabis.
About Integrated Cannabis Company, Inc.
Integrated Cannabis Company, Inc. is comprised of dedicated scientists and product engineers who are passionate about health and creating health and lifestyle products utilizing advanced delivery systems and formulations. For more information, please visit the company's website at: http://www.x-sprays.com.
ON BEHALF OF THE BOARD "John Knapp" Chief Executive Officer
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
For further information, please contact: Telephone: +778-403-3358
SOURCE Integrated Cannabis Company, Inc.
Subscribe to our Free Newsletters!
FDA approved elapegademase-lvlr injection for intramuscular use is used as an enzyme replacement ...
Armpit lumps and raised bumps in the armpits caused by infection, cysts and other types of ...
Bad eating habits will affect your health as well as your skin and make you look older than your ...View All